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Evaluation and treatment of coronary artery disease in patients
with end-stage renal disease. Patients with end-stage renal dis-
ease (ESRD) are at increased risk of death from coronary artery
disease (CAD). The metabolic milieu that results from renal
dysfunction appears to accelerate the atherosclerotic process
by decades in patients with ESRD. The extremely high preva-
lence of atherosclerosis in patients with ESRD mandates risk
factor identification and treatment. Traditionally, CAD in this
patient population has been treated conservatively. Analysis
of large databases has highlighted the scope and complexity
of this problem; nonetheless, there is a paucity of randomized,
controlled trials of CAD in patients with ESRD. In this pa-
per the following issues related to evaluation and treatment of
patients with chronic kidney disease are addressed: (1) optimal
CAD risk management; (2) evaluation for CAD in patients with
ESRD, including the identification of coronary calcification; (3)
treatment of CAD with medical therapy and revascularization;
(4) relative merits of percutaneous coronary intervention ver-
sus bypass surgery. In general, an aggressive approach to med-
ical management of CAD is warranted, even in the setting of
subclinical CAD. A low threshold for diagnostic testing should
be employed in patients with ESRD. When significant CAD is
identified, ESRD patients appear to benefit more from revas-
cularization compared to conservative medical management.
Thus, if clinically reasonable, patients with ESRD and CAD
should be managed aggressively to improve survival and reduce
the incidence of future cardiac events.
Patients with end-stage renal disease (ESRD) are at
increased risk of death from cardiac causes [1]. The
prevalence of angiographically significant coronary
artery disease (CAD) ranges from 25% in young, non-
diabetic hemodialysis patients [2] to 85% in older ESRD
patients with longstanding diabetes [3]. It has been esti-
mated that the risk of cardiac death in dialysis patients
younger than age 45 is 100 times greater than that the gen-
eral population [4]. Even more striking is that, while only
0.1% of the population requires dialysis in the United
States, more than 2.5% have some degree of renal in-
sufficiency, and these individuals with chronic kidney
disease are also at increased risk of cardiovascular dis-
ease and its complications [5]. Chronic kidney disease
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(CKD) can be defined in 5 stages [6]. Detectable risk for
procedural complications typically occurs below an es-
timated glomerular filtration rate of 60 mL/min/1.73m2.
This article will focus on stage 5 CKD, which is mainly
composed of those patients with ESRD on maintenance
dialysis.
The prevalence and severity of CAD among patients
with ESRD is daunting in terms of both occurrence and
extent of poor outcomes. Medicare beneficiaries with kid-
ney disease who are not yet on dialysis are 60% more
likely to have a billing claim submitted for the diagnosis
of cardiovascular disease (CVD), and 70% more likely
to have a claim submitted for “atherosclerotic heart dis-
ease” [7]. At the time of initiation of dialysis, a substantial
proportion, perhaps the majority, had established CAD
[8, 9]. In diabetic renal transplant candidates, 30% will
have one or more lesion with greater than 75% steno-
sis [10]. When compared to patients without CKD who
undergo evaluation for CAD, those with ESRD have sub-
stantially more numerous and severe coronary artery le-
sions, as well as more severe left ventricular dysfunction
[11, 12].
Moreover, patients with ESRD have poor outcomes
from CAD. In 3106 patients with acute myocardial in-
farction (AMI), in-hospital mortality rates were 2% in
patients with normal renal function, 6% in those with mild
renal dysfunction, 14% in those with moderate renal dys-
function, 21% in those with severe renal dysfunction, and
30% in those with ESRD [13]. A comparable directional
trend was observed for increasing risk of postdischarge
death with advancing degrees of CKD [7]. Similarly, in a
group of 34,189 patients on long-term dialysis who were
hospitalized for a first myocardial infarct, the mortality
rate from cardiac causes was 40.8% at 1 year, 51.8% at
2 years, and 70.2% at 5 years [14]. Overall, CVD accounts
for approximately 50% of ESRD deaths [7]. Despite this
high mortality rate after AMI, and although rates of mor-
tality for all cardiovascular diseases have increased 14.5%
since 1991, mortality rates due to atherosclerotic heart
disease and AMI have fallen 13% to 15% among patients
with CKD [7].
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Table 1. Therapeutic opportunities to improve cardiovascular care in patients with end-stage renal disease
Therapeutic opportunity Rationale
Weight loss/weight maintenance at BMI ≤25 kg/m2 Improvement of the dysmetabolic syndrome and diabetes
Low sodium intake Reduce blood pressure
Make blood pressure more responsive to medications
Reduce volume retention between dialysis sessions
Aspirin 81 mg p.o. qd or clopidogrel 75 mg p.o. qd if aspirin intolerant Primary prevention of AMI and stroke
Lipid control (diet, statin, fibrates, niacin, others) Primary prevention of AMI, stroke, and CVD death
LDL-C <100 mg/dL Possible reduction in progression of CKD
TG <150 mg/dL
HDL-C >50 mg/dL
Blood pressure control to target of SBP <130 mm Hg Primary prevention of AMI, stroke, heart failure, and CVD death
RAAS blocking agents Preserve residual urine volume in peritoneal dialysis patients
Beta-blocking agents Reduce left ventricular hypertrophy
Other add-on agents Treatment of subclinical cardiac ischemia
Blood glucose control in diabetes Reduction in risk of AMI, stroke, and CVD death
Reduction in worsened nephropathy/retinopathy
Reduce homocysteine Possible reduction in risk of AMI, stroke, and CVD death
–Folic acid
–Vitamin B6 and B12
Abbreviations are: BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; SBP, systolic
blood pressure; RAAS, renin angiotensin aldosterone system; AMI, acute myocardial infarction; CVD, cardiovascular disease; ESRD, end-stage renal disease. Adapted
from reference [55].
OPTIMAL MEDICAL THERAPY
The patient with incipient ESRD on maintenance dial-
ysis should be considered to be the highest cardiovascular
risk patient in medicine, with an expected rate of coro-
nary heart disease (CHD) death that is many-fold the
rate expected for a non-ESRD patient in whom every
conventional cardiovascular risk factor is present [15].
Thus, ESRD is more than a cardiovascular risk equiv-
alent. Hence, in ESRD patients, therapeutic strategies
should be undertaken that are even more aggressive than
those recommended in conventional guidelines (Table 1).
Blood pressure control
Despite the use of multiple medications, most pub-
lished series of ESRD patients from either clinical trials
or registries indicate that the mean systolic blood pres-
sure is approximately 155 mm Hg. This reflects the fact
that 80% of ESRD patients have hypertension (HTN),
and that it is adequately controlled in only 30% [16].
Long-term cardiorenal protection involves 2 important
concepts: blood pressure control to a much lower target
of a systolic blood pressure (SBP) <130 mm Hg [17],
and use of an agent that blocks the renin-angiotensin
aldoserterone system (RAAS), such as an angiotensin-
converting enzyme inhibitor (ACEI) or an angiotensin
receptor blocker (ARB) as the base of therapy. How can
an ACEI/ARB be effective in a patient with ESRD—
particularly one who is anephric? The RAAS angiotensin
system appears to have considerable redundancy, and
is able to maintain systemic function, if not increase its
overall level of activity without participation by the kid-
neys [18]. Hence, this hyperactivation of the RAAS is a
target for therapy in ESRD. In this regard, ACEI and
ARB treatment has been shown to reduce LVH and im-
prove myocardial function in ESRD. Clinical outcomes
evidence for the benefit of ACEI/ARB in the general
population also extends to ESRD patients [19]. Very im-
portantly, a recent trial has demonstrated that ramipril
was related to preservation of residual urine output in
those receiving peritoneal dialysis, which is a consistently
favorable management issue in ESRD [20]. One study
has demonstrated that although only approximately 20%
of patients with ESRD and CAD receive ACEI, those
who were given these agents after CAD events had im-
proved all-cause mortality over the next 5 years [21].
Unfortunately, treatment with ACEI/ARB may result
in worsening hyperkalemia in patients with ESRD. As
tolerated, the clinician should consider adjusting the dia-
lytic regimen to optimize potassium balance and continue
treatment with ACEI/ARB. To date, available evidence
indicates that patients with ESRD appear to benefit from
ACEI/ARB therapy provided the serum potassium and
blood pressure can be adequately controlled.
With an ACEI/ARB as a base of therapy, the antihy-
pertensive regimen can be further modified according to
blood pressure lowering efficacy and CAD event reduc-
tion. Beta-blockers can be used as both an antihyperten-
sive and an anti-ischemic agent [22]. In patients with heart
failure, beta-blockers improve left ventricular ejection
fraction, reduce rates of hospitalization, sudden death,
and all-cause mortality [23, 24]. Studies have demon-
strated large relative risk reductions in all-cause mortality
for patients with ESRD who receive beta-blockers ther-
apy after CAD events [24].
If the blood pressure cannot be adequately controlled
with ACEI/ARB and beta-blockers therapy, additional
antihypertensive agents can be added to the regimen
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based on ease of management, compliance, and lack of
adverse effects. The goal is to create a blood pressure en-
vironment for the cardiovascular system where the mean
systolic blood pressure, on 24-hour monitoring, for ex-
ample, is at or below 130 mm Hg. Guidelines for non-
ESRD patients state the optimal systolic blood pressure
should be <120 mm Hg [17]. This goal is often difficult
to achieve in patients with ESRD while avoiding intradi-
alytic hypotension. Given the high rates of severe CAD
in ESRD, hypotension during dialysis almost certainly is
related to clinical and subclinical myocardial ischemia,
which should be suspected in the presence of chest dis-
comfort, shortness of breath, ST-segment depression on
electrocardiography, or elevations of cardiac troponins
on blood testing [25].
The key lifestyle changes with ESRD that can assist
with blood pressure control include dietary sodium re-
striction (2–4 g/day), weight reduction to a target body
mass index <25 kg/m2, and exercise for 60 minutes per
day most days of the week. Limiting alcohol intake to 1
drink or less (14 g of alcohol) per day is also a valuable
tool in the nonpharmacologic management of hyperten-
sion [17].
Treatment of dyslipidemia
Data are, in general, supportive of low-density lipopro-
tein cholesterol (LDL-C) reduction, in most cases with
HMG CoA reductase inhibitors (statins), in patients with
ESRD with an expected relative risk reduction in CVD
events [26, 27]. The most common dyslipidemia profile
consists of an elevated triglyceride (TG) level, depressed
high-density lipoprotein cholesterol (HDL-C), and mod-
estly elevated LDL-C. Agents that reduce TG and raise
HDL-C, including nicotinic acid and fibrates, can be used
according to the National Cholesterol Education Project
Adult Treatment Panel III (NCEP-ATP-III) Guidelines
[28].
Blood glucose control in diabetics with end-stage
renal disease
In ESRD with diabetes, blood glucose control to a tar-
get glycohemoglobin <7 mg/dL can be expected to re-
duce rates of microvascular disease (retinopathy) and, to
a lesser extent, clinically important atherosclerotic dis-
ease elsewhere (AMI, stroke, CVD death) [29].
Smoking cessation
Although reported rates of smoking are lower in ESRD
patients than the general population, it is worth men-
tioning this important risk factor since it has been clearly
shown to raise CVD death rates in ESRD to very high lev-
els [30]. The nicotine in cigarette smoke becomes addic-
tive to the human body at a daily dose above 5 cigarettes
per day [31]. The many components of “tar” in cigarette
smoke have been linked to the up-regulation of adhesion
molecules and other factors that promote oxidation and
entry of LDL-C into the vascular subendothelium [32].
This process can occur at any dose of cigarette smoke,
including sidestream smoke. Hence, there is a strong ra-
tionale for encouraging patients to wean down to below
5 cigarettes per day, and then create a cessation plan with
nicotine replacement if needed. In patients with estab-
lished CAD, those who have successfully stopped smok-
ing have enjoyed approximately 50% risk reduction in
all-cause mortality [33].
Antiplatelet agents
Primary prevention measures for CVD event reduction
in the general population apply to the patient with early
nephropathy. Low-dose aspirin (81 mg daily) has been as-
sociated with a 20% to 30% reduction in the risk of stroke,
AMI, and CVD death across many populations [34]. The
effect of aspirin on renal end points is unknown; how-
ever, given its CVD protective effect, it is recommended
for adult patients with ESRD [35]. For those who are
aspirin intolerant, general cardiology guidelines recom-
mend the use of clopidogrel, although there are no pub-
lished studies of clopidogrel on cardiovascular outcomes
in the setting of ESRD.
Novel risk factors
Patients with ESRD are known to have markedly ele-
vated levels of homocysteine and other thiols [36]. Given
the reported association of gradations of homocysteine
elevation to increased ESRD mortality, it is reasonable
to provide some attempt at homocysteine reduction in
ESRD patients until we have results from clinical tri-
als [37]. Homocysteine reduction is largely accomplished
with supplemental folic acid, which can be used up to 25 g
orally per day. Vitamins B6 (pyridoxine) and B12 are also
needed, but in more conventional quantities (25 mg and
1 mg, respectively). The usual doses required to bring a
predialysis homocysteine level near the 14 lmol/L target
is 1 to 5 g per day. However, studies have shown it is dif-
ficult if not impossible to “normalize” homocysteine in
patients with ESRD [38].
Another area of interest is the role of inflammatory
factors and cytokines as novel risk markers in ESRD.
The most commonly reported nonspecific measure of
systemic inflammation in ESRD is high-sensitivity C-
reactive protein (hs-CRP) [34]. Studies have consistently
shown that ESRD is an inflammatory state with levels
of hs-CRP typically higher that the fourth quartile of
most asymptomatic, disease-free populations [39]. Unfor-
tunately, data regarding the utility of hs-CRP measure-
ments are heavily confounded by a multitude of other
CVD-modifying features, such as smoking, dyslipidemia,
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Fig. 1. The processes related to the acceleration of coronary disease and plaque rupture in patients with renal disease. NO, nitric oxide; LDL-C,
low-density lipoprotein cholesterol; AGE, advanced glycation end products. Reproduced with permission from reference [41].
physical inactivity, obesity, and diabetes. However, med-
ications including statins and some diabetes medications
lower hs-CRP. It should be noted that therapeutic inter-
vention specifically aimed at reduction of hs-CRP is not a
proven strategy, but to the extent that hs-CRP is lowered
by weight reduction, glucose control, and lipid control,
it can be viewed as a favorable sign. Lastly, hs-CRP can
serve as a reminder that those with the highest levels of
this factor will benefit from a markedly reduced relative
risk for future CAD events provided they take aspirin 81
to 325 mg daily [40].
Finally, deposition of advanced glycation end products
and reduced nitric oxide availability have both been im-
plicated in acceleration of anatomic CAD disease, and
with increase risk of acute rupture of coronary plaques
(Fig. 1). Since patients with ESRD and coronary artery
disease are at high risk for cardiovascular events, they rep-
resent a unique and instructive population for researchers
interested in the pathogenesis of atherosclerosis.
Coronary artery calcification in patients with end-stage
renal disease
An attractive hypothesis accounting for the high rates
of CAD events in ESRD is the abnormal and acceler-
ated vascular calcification that occurs in these patients
[41–43]. The calcification in ESRD is thought to occur
at 2 sites in the vessel wall, including the media, where
it is known as Mo¨nckeberg’s sclerosis, and in the intima,
where it is invariably associated with atherosclerosis. Cell
biology studies suggest that coronary artery calcification
is an active process analogous to bone formation, given
that several genes characteristic of the osteoblast phe-
notype are also expressed by calcifying vascular smooth
muscle cells (VSMC) [44]. Bone matrix proteins, includ-
ing osteocalcin, matrix Gla protein, and osteopontin have
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Fig. 2. Postulated three-step mechanism in the induction of uremic
vascular calcification: (1) vascular smooth muscle cells dedifferentiate
to become osteoblast-like; (2) osteoblast-like cells lay down a matrix
of collagen and noncollagen proteins that serve as a nidus for subse-
quent mineralization; (3) promineralizing forces (increased calcium-
phosphorus product, hyperphosphatemia, or increased calcium load)
outweigh the antimineralizing forces of inhibitors (fetuin and matrix
Gla protein). Cbfa1, a transcription factor for osteoblast differentia-
tion and the expression of the bone matrix proteins; MGP, matrix gla
protein; Pi, phosphorus. Reproduced with permission from reference
[45].
rived from work with modified VSMCs (which arise from
the same pluripotent cell as does the osteoblast) suggest
that elevated phosphorus concentration in the culture
medium can lead to calcification, and induce Cbfa1 (a
transcription factor critical for osteoblast differentiation
and the expression of the bone matrix proteins osteopon-
tin, osteocalcin, and type I collagen) and the expression
of bone matrix proteins. Hyperphosphatemia, a labora-
tory abnormality common in ESRD patients, therefore,
could represent an important stimulus by which uremia
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Total cholesterol ≥200 mg/dL
HDL <35 mg/dL
Family history of premature cardiac disease
Fig. 3. Algorithm for evaluation of patients with ESRD for suspected coronary artery disease (adapted from reference [41]).
predisposes to excessive vascular calcification (Fig. 2)
[45–47]. The effect of calcium loading with or without
changes in the serum calcium on the basic processes lead-
ing to vascular calcification is unknown. A recent system-
atic review concluded that clinical studies in ESRD sug-
gest the process is driven much more by the patient’s age,
length of time on dialysis, and lipid status [48]. While it
may appear that phosphorus level and mortality are re-
lated, the causal pathway is poorly understood, though
some recently postulated mechanisms are listed below.
Moreover, it is also not clear whether or not the increased
mortality risk associated with hyperphosphatemia is sec-
ondary to coronary artery calcification [48].
A recent study in patients with ESRD on dialysis
demonstrated that there is no significant positive correla-
tion between the severity of coronary artery calcification
measured by EBCT and the degree of occlusive coronary
artery disease [49]. However, the total absence of any
CAC strongly correlated with the absence of significant
atherosclerotic disease. Although the numbers of patients
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examined were small, the study was powered to detect a
significant correlation (if it was present) between individ-
ual CAC score and plaque burden (power = 0.93, N =
52 vessels) [49]. Does attenuation of the progression of
CAC in ESRD patients, when the score is already at high
levels, reduce the chances of a CAD event attributed to a
calcified lesion? This critically important question will be
difficult to answer since the therapies (statins and seve-
lamer) that attenuate progression do so primarily by re-
ducing LDL-C, and likely stabilizing less severe plaques
elsewhere in the coronary bed [44]. Currently, routine
testing for CAC or specific treatment based on the find-
ing of CAC in ESRD patients is not recommended. Treat-
ment strategies for use of dietary phosphate binders and
other drugs that influence calcium-phosphorus balance
should be based on the need to achieve K/DOQI guide-
lines for control of serum calcium and phosphorus, Ca
× P product, and PTH rather than on the basis of a the
coronary artery calcification score, per se.
Diagnostic testing for coronary disease
With regard to noninvasive screening tests for CAD,
the utility and predictive ability of decision statistics
(sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy) varies for different studies
depending on the population tested and the gold stan-
dard utilized for the diagnosis of CAD. Details regarding
each possible test, potential difficulties in their utilization
among patients with ESRD, and their decision statistics
have been summarized previously [50]. In general, any
ESRD patient with cardiovascular symptoms, signs of
ischemia during dialysis (chest pain, ST-segment changes,
or elevation of cardiac troponin levels), and those await-
ing renal transplantation should undergo diagnostic
testing for CAD (Fig. 3) [50]. Standard testing with a
nuclear stress test or stress echocardiography should be
undertaken. Deconditioning, amputations, obesity,
arthritis, and other factors often make exercise im-
possible; hence, dipyridamole or adenosine nuclear or
dobutamine echocardiographic should be performed
[50]. Currently, given the ubiquitous nature of coronary
artery calcium in ESRD, use of electron beam or
ultrafast computed tomography is not recommended
[51]. Once significant CAD has been found, there is
considerable controversy over the optimal approach to
revascularization [52].
Coronary revascularization in ESRD
Three analyses suggest that patients with ESRD and
coronary artery disease who receive conservative med-
ical management tend to fare the worst among all
treatment groups [53–55]. Therefore, in the absence of
life-threatening comorbid conditions, most ESRD pa-
tients are candidates for angiographic evaluation and pos-
Table 2. Risks associated with coronary revascularization in patients




AMI (with or without ST elevation) 2.0–23%
Stroke 0.6–2.5%
Major bleeding 0–43.1%




Need for emergent CABG 0–5%
CABG
Short-term mortality 0–31%
AMI (with or without ST elevation) 4.2–18%
Stroke 0–20%
Major bleeding 3–11%




ESRD = end-stage renal disease; AMI = acute myocardial infarction; PCI =
percutaneous coronary intervention; CABG = coronary artery bypass surgery.
sible revascularization. At angiography, multivessel CAD
is the most frequent finding, and so the next question is
what is the optimal approach—multivessel percutaneous
coronary intervention (PCI) or coronary artery bypass
grafting? It is widely accepted that patients with ESRD
undergoing mechanical coronary revascularization pro-
cedures are at increased risk for adverse events includ-
ing death (Table 2). Dialysis-dependent patients under-
going CABG face a 4.4 times greater risk of in-hospital
death, a 3.1 times greater risk of mediastinitis, and a
2.6 times greater risk of stroke compared to those pa-
tients undergoing CABG who were not on dialysis [54].
While newer surgical techniques have been successful in
high-risk patients with renal failure, the long-term results
compared to traditional surgical and percutaneous tech-
niques are not yet known. In general, despite this signifi-
cant “upfront” risk of surgery, the literature suggests that
in patients with ESRD, outcomes for CABG are supe-
rior to those achieved with percutaneous interventions
[51]. In single-vessel CAD and multivessel CAD without
good bypass targets, recent trends suggest that PCI with
stenting is a favorable approach for patients with ESRD
(Fig. 4) [51]. It is possible that increased utilization of
drug-eluting stents in patients with ESRD will favorably
impact the high restenosis rates typically seen in this pop-
ulation, and may tip the risk-benefit scale in favor of per-
cutaneous intervention.
CONCLUSION
Patients with ESRD have more than coronary artery
disease risk equivalent status in their baseline CAD
risk assessment. An aggressive approach to medical
























Fig. 4. Long-term survival according to CAD management strategy in
patients with CrCl<60 ml/min or with ESRD on dialysis (Reproduced
with permission from reference 45).
management for coronary artery disease is warranted,
even in the setting of subclinical disease [55]. A low
threshold for diagnostic testing should be employed in
ESRD patients. When significant CAD is found, ESRD
patients appear to benefit from revascularization com-
pared to conservative medical management, and if clin-
ically reasonable, should be given that opportunity for
improved survival and reduction in future cardiac events.
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